Travere Therapeutics' Cash from Discontinued Operations fell 16.21% to -$7.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$7.5 million, marking a year-over-year decrease of 116.44%. This contributed to the annual value of -$7.5 million for FY2024, which is 116.44% down from last year.
Latest data reveals that Travere Therapeutics reported Cash from Discontinued Operations of -$7.1 million as of Q4 2024, which was down 14,278.00% from $50,000 recorded in Q3 2024.
Travere Therapeutics' Cash from Discontinued Operations' 5-year high stood at $22.1 million during Q4 2022, with a 5-year trough of -$7.1 million in Q4 2024.
For the 3-year period, Travere Therapeutics' Cash from Discontinued Operations averaged around $6.7 million, with its median value being $50,000 (2024).
Data for Travere Therapeutics' Cash from Discontinued Operations shows a maximum YoY slumped of 127.65% (in 2023) over the last 5 years.
Over the past 3 years, Travere Therapeutics' Cash from Discontinued Operations (Quarterly) stood at $22.1 million in 2022, then slumped by 127.65% to -$6.1 million in 2023, then dropped by 16.21% to -$7.1 million in 2024.
Its Cash from Discontinued Operations stands at -$7.1 million for Q4 2024, versus $50,000 for Q3 2024 and -$309,000 for Q2 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value